• English
  • Korean
  • Chinese
表紙
市場調査レポート - 203833

世界の幹細胞技術市場展望

Stem Cell Technologies: World Market Outlook 2013-2023

発行 Visiongain
出版日 ページ情報 英文 151 Pages
価格
世界の幹細胞技術市場展望 Stem Cell Technologies: World Market Outlook 2013-2023
出版日: 2013年08月02日 ページ情報: 英文 151 Pages
概要

幹細胞製品およびサービスは投資、技術進歩および販売において大きな可能性があります。世界の幹細胞技術市場は2013年から2023年に高成長を達成し、2017年には107億米ドルに達すると予測されています。

当レポートでは、幹細胞の治療応用、技術動向、製品、サービス概要をまとめ、セグメント別の予測などを提供しており、SWOT分析、専門家の見解とともに、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 幹細胞技術の概要

  • 強い市場実績の予測
  • 癌セグメントは幹細胞療法収益のほとんどを示す
  • どのタイプの幹細胞が市場にとって重要か?
  • 世界の幹細胞規制環境

第3章 幹細胞治療セグメント

  • HSCTは癌セグメントの成長を支える見込み:2013年〜2023年
  • 幹細胞:血液癌治療の主要部分としての45年
  • 最初の認可によるパイプラインの成熟
  • 癌適応症において幹細胞はどれだけの成長潜在性を持っているか?

第4章 幹細胞心血管治療セグメント

  • セグメントはCAGR40%以上の見込み:2013年〜2023年
  • 幹細胞は心臓・血管系を治せるか?
  • 心血管幹細胞パイプライン・製品
  • 幹細胞は心血管の領域におけるゲームチェンジャーとなるか?

第5章 幹細胞CNS(中枢神経系)治療セグメント

  • 最大の幹細胞療法革命の全ては2023年までに形成され始める
  • 幹細胞は多くの深刻なCNS疾患にとって最大の望み
  • CNSにおける最初の第3層試験となるのはどの製品か?
  • CNS幹細胞は認められた治療可能性を実現できるか?

第6章 その他の疾病領域における幹細胞治療

  • 多様な認可範囲がセグメントの成長を後押し
  • 幹細胞治療のその他の適応症
  • どの適応症が最初に認可されるか?
  • 2023年までにその他の治療領域で幹細胞の臨床における飛躍的進歩を期待できるか?

第7章 幹細胞技術セグメントの非治療アプリケーション

  • セルベースアッセイは同セグメントの拡大を助ける
  • 新興する多様な範囲のビジネスモデル
  • 非治療幹細胞活動にとっての主要な成長領域は?

第8章 産業の定性分析

  • 強み:幹細胞は遂にその価値を証明
  • 弱み:克服すべき多くの問題が残る
  • 機会:幹細胞はかつてない臨床的可能性を持つ
  • 脅威:規制・商業的不安点性が市場を脅かす
  • 社会的懸念事項:賛否両論の技術
  • 技術的発展:幹細胞科学は発展途上
  • 経済要因:資金不足の心配
  • 政治的問題:研究開発には州の態度が鍵

第9章 調査インタビュー

第10章 結論

  • 幹細胞技術は2017年までに飛躍的進歩が始まる
  • 市場は2023年まで2桁のCAGRを記録する
  • 2017年まで癌・非治療用途が支配的
  • 2023年までにCNS・心血管治療が市場シェアを獲得する
  • 強いR&Dパイプラインが市場成長を促進する
  • 長期的には幹細胞の根本的な臨床的・商業的可能性
  • 幹細胞市場の課題
  • 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Stem cells: why that market can expand - you discover its sales potential

What are the commercial prospects for stem cells? Visiongain's updated report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends, technologies, therapies, and opportunities.

That study gives you revenue forecasts to 2023 for the overall world market and its submarkets. See what's happening for those cellular technologies, finding how you can gain.

Read on to explore that industry and see what its future market could be worth.

Forecasts 2013-2023 and other analyses - find the best opportunities

Besides revenue forecasting to 2023, our new work shows recent results, growth rates, and market shares. There you find original analysis. See research and development (R&D) too. You also get 40 tables, 22 charts, and three interviews with organisations in the field.

Now make your search for data on stem cells easier. You can stay ahead in knowledge, then, benefiting your research, analysis, and decisions. Also save time.

Our new study lets you investigate the most promising and lucrative parts of that field - assess technologies and their applications. You hear what's going on and see where the money lies. Try our new report, then, getting feel for the stem cell industry's potential.

The following sections show how you benefit from that investigation.

Prospects from 2013 for the world market and submarkets

What are the secrets of that industry's progress? Along with our prediction of the overall world market for stem cells, our work shows you individual revenue forecasting of five submarkets to 2023 at world level:

  • Cancer (oncology)
  • Cardiovascular diseases
  • Central nervous system (CNS) disorders
  • Other therapeutic applications
  • Non-therapeutic uses.

See how and why those segments can prosper. That analysis helps you identify potential for stem cell products and services. Assess how tools and systems can make money.

There you also explore challenges and strengths of that industry and market, helping you compete and gain advantages. You see prospects for established and emerging technology. That market will grow through the approval and launch of many products.

Our study explains, discussing issues to help your work.

Developments, challenges, and opportunities affecting stem cells

The report lets you assess trends and outlooks for stem cells. There, looking ahead, you find discussions of issues and developments:

  • Efforts and outlooks in the US, Japan, Europe, South Korea, China, and Israel
  • Regulations and ethics for stem cell research and uses in medicine
  • Embryonic stem cells (ESCs) and induced pluripotent adult cells (IPSCs)
  • Haematopoietic stem cell transplantation (HSCT)
  • Uses for umbilical cord blood and related technologies
  • Supply, storage (banking) and processing of the cellular material.

That investigation discusses other aspects of stem cell technology too, including these:

  • Activities of Osiris Therapeutics, Gamida Cell, Novartis, Baxter, NeoStem, and others
  • Approvals of therapies and other products to expand and progress the sector
  • Orphan diseases and other under-treated conditions
  • Metabolic applications - diabetes and liver treatments
  • Agents for osteogenesis and treating autoimmune disorders
  • Cell-based assays - uses in diagnostic tests and devices.

There you explore political, economic, social, and technological questions, assessing advances and outlooks for business. You also gain regulatory insights. See, then, what stimulates and restrains organisations in that industry.

For example, the author of the report said: "Companies are targeting ischaemic disorders of the cardiovascular and cerebrovascular systems, in 2012 the biggest causes of death worldwide. More than 20 stem cell products tackling those diseases are in clinical trials."

Discover, then, what the present and future hold.

Stem cells - what 2017 market value?

What happens next? From 2013, stem cell products and services hold great potential for investments, technological advances and sales. Our new report predicts the world market for those technologies will reach $10.7bn in 2017, achieving high growth from 2013 to 2023.

Prospects for those medical tools and systems are strong, and from 2013 to 2023 there will arise many opportunities. Our analyses show you the possibilities, helping you stay ahead.

Information found nowhere else

In particular, then, our new study gives you these advantages:

  • Revenues to 2023 for stem cells at world level, with forecasting of five submarkets - assess prospects for investments and sales
  • Interviews with other authorities - discover what participants from industry and academia think, say, and do, helping you stay ahead
  • Prospects for established competitors and new entrants - explore activities, results, R&D, and outlooks for future success.

Stem Cell Technologies: World Market Outlook 2013-2023 gives independent analysis. There you receive business intelligence found only in our work, finding where money lies.

With that report you are less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Explore progress and possibilities. Also find how you can save time and get recognition for insight.

Stem cells - assess commercial potentials now, seeing what you can gain

Our new report is for everyone analysing biotechnology for healthcare - pharmaceuticals, diagnostics, and medical devices. There you find sales predications with discussions. Avoid missing out - please order the report now.

Table of Contents

1. Executive Summary

  • 1.1 Overview of Findings
  • 1.2 Chapters in the Report
  • 1.3 Research and Analysis Methods

2. Overview of the Stem Cells Market, 2013-2023

  • 2.1 Strong Market Performance Expected 2013-2023
  • 2.2 Cancer Segment Represents Bulk of Stem Cell Therapy Revenues, 2013
    • 2.2.1 Other Therapeutic Areas to Gain Ground by 2023
    • 2.2.2 Market Breakdown Focuses on Key Therapeutic Areas
  • 2.3 Which Types of Stem Cells Matter for the Market?
    • 2.3.1 The Discovery of Stem Cells
    • 2.3.2 Embryonic Stem Cells (ESCs) Enter the Picture
    • 2.3.3 Only ESCs and Induced Pluripotent Adult Cells (IPSCs) Have Pluripotency
    • 2.3.4 MSCs Prominent in Clinical Trials
    • 2.3.5 Autologous and Allogeneic Properties
    • 2.3.6 Different Cell Advantages and Disadvantages
  • 2.4 The Global Regulatory Environment for Stem Cells
    • 2.4.1 US: No Morality Clause, Much Venture Capital
      • 2.4.1.1 ESC Controversy Now Settled?
      • 2.4.1.2 FDA Vs Regenerative Sciences
    • 2.4.2 Japan: Liberal on hESCs
      • 2.4.2.1 First-in-Human iPSC Trial Announced in 2013
    • 2.4.3 Europe: No Consistent Position Across the Continent
      • 2.4.3.1 The Brüstle Ruling: Dead and Buried?
      • 2.4.3.2 The UK Leads in European Stem Cells R&D
    • 2.4.4 Rest of the World
      • 2.4.4.1 South Korea: Leading the Way in MSC Approvals
      • 2.4.4.2 China: Liberal Laws on Stem Cell Research
      • 2.4.4.3 Israel - Long-Term Research Activity
      • 2.4.4.4 'Stem Cell Tourism'

3. Stem Cell Cancer Therapeutics Segment 2013-2023

  • 3.1 HSCT Will Underpin the Growth of the Cancer Segment in the 2013-2023 Period
  • 3.2 Stem Cells: 45 Years as a Major Part of Blood Cancer Treatment
    • 3.2.1 Autologous HSCT Operations Still Dominate Segment
    • 3.2.2 Allogeneic HSCT: More Rejections, Fewer Relapses
    • 3.2.3 GvHD: The Major Issue for HSCT
    • 3.2.4 Peripheral Blood: More Anti-Tumour Effect, More GvHD Risk
    • 3.2.5 The Rise of Umbilical Cord Blood
    • 3.2.6 Around 60,000 HSCT Operations Performed Worldwide in 2012
    • 3.2.7 HSCT Costly, Medicare Coverage Selective
    • 3.2.8 Haematological Malignancies the Major Indication for HSCT
    • 3.2.9 HSCT Addresses Cancers Representing a $20bn+ Market
    • 3.2.10 From Successful Procedure to Successful Products? The Next Stage for the HSCT Sector
  • 3.3 Pipeline Maturing, with First Approval in 2012
    • 3.3.1 Osiris Therapeutics - Prochymal Finally Makes it to Market
      • 3.3.1.1 Osiris Leads the Pack in Stem Cell Therapeutics
      • 3.3.1.2 Using MSCs for Immunosuppression
      • 3.3.1.3 Positive Results in Acute Paediatric GvHD
      • 3.3.1.4 An Important Role to Play in the Future of HSCT
    • 3.3.2 The Clinical-Stage Pipeline: Two More Candidates in Phase 3
    • 3.3.3 Gamida Cell - StemEx: The Next Stem Cell Product to Market?
      • 3.3.3.1 Survival at 100 Days Improved by StemEx in Latest Trial
      • 3.3.3.2 FDA Remains Unconvinced
      • 3.3.3.3 NiCord Heads Up a Pipeline of New Cell Therapy Products
      • 3.3.3.4 NiCord Promising So Far
    • 3.3.4 Mesoblast - Using Mesenchymal Precursors to Enrich Cord Blood
      • 3.3.4.1 Phase 3 Trial Measuring 100-Day Survival Rates and Engraftment Efficiency
      • 3.3.4.2 A Competitor for Gamida Cell?
    • 3.3.5 Novartis Pharmaceuticals - Cord Blood Transplant Candidate
      • 3.3.5.1 Swiss Giant with Multiple Stem Cell Interests
    • 3.3.6 Medipost - Promostem Uses Cord Blood MSCs to Prevent GvHD
    • 3.3.7 CytoMedix - Improving Engraftment
    • 3.3.8 Lentigen - LG631-CD34 for Chemoprotection
    • 3.3.9 Athersys - MultiStem Trialled in Blood Cancers
    • 3.3.10 HomeoTherapy - MSCs for GvHD
    • 3.3.11 Pluristem Soon to Join the Hunt?
    • 3.3.12 Other Stem Cell Oncology Prospects
    • 3.3.13 Ancillary Products for the HSCT Setting
    • 3.3.14 Targeting Cancer Stem Cells (CSCs)
    • 3.3.15 Immunovative Therapies - Building on HSCT for a Cellular Anticancer Therapy
  • 3.4 How Much Growth Potential Do Stem Cells Have in Cancer Indications?

4. Stem Cell Cardiovascular Therapeutics Segment, 2013-2023

  • 4.1 Segment Set for 40%+ CAGR in 2013-2023 Period
  • 4.2 Can Stem Cells Heal the Heart and Vasculature?
    • 4.2.1 AMI, CLI and Stroke Major Ischaemic Disease Targets
    • 4.2.2 Cerebrovascular Treatments for Stroke
    • 4.2.3 What is the Heart's Own Stem Cell?
    • 4.2.4 MSCs Support Cardiac Stromal Lineages
    • 4.2.5 The Mysterious Efficacy of Adult Stem Cells in the Heart
    • 4.2.6 Cells Have Therapeutic Effects Despite Rapid Clearance
    • 4.2.7 A New Generation of Cardiovascular Stem Cells May Need to Look Beyond MSCs
    • 4.2.8 Are MSCs Safe and Efficacious?
    • 4.2.9 Cardiovascular and Cerebrovascular Conditions Are World's Most Fatal Diseases
    • 4.2.10 Cardiovascular Drugs Market Exceeded $110bn in 2012
  • 4.3 Cardiovascular Stem Cell Pipeline and Products, 2013-2023
    • 4.3.1 FCB-Pharmicell - Hearticellgram-AMI, the First Approved Cardiovascular Stem Cell Treatment
      • 4.3.1.1 Performance So Far
      • 4.3.1.2 Will Hearticellgram Impress Regulators Outside Korea?
    • 4.3.2 The Largest Pipeline in the Stem Cells Market
    • 4.3.3 Baxter: Big Pharma Leader in Cardiovascular Stem Cells
      • 4.3.3.1 Exercise Tolerance and Angina Frequency Reduced
      • 4.3.3.2 Wider Potential for this Treatment
    • 4.3.4 Cardio3 Bioscience - Cardiopoiesis Platform for Heart Regeneration
      • 4.3.4.1 Positive Phase 2 Data
      • 4.3.4.2 Phase 3 Trial Begins Amid Controversy
    • 4.3.5 Bioheart - MyoCell in new MIRROR Trial
      • 4.3.5.1 Muscle Cells the Basis of MyoCell
      • 4.3.5.2 Seeking Expanded Access for Compassionate Use
    • 4.3.6 NeoStem - Diversified Outfit with One of the Leading Candidates
      • 4.3.6.1 AMR-001 to Treat Acute Myocardial Infarction
      • 4.3.6.2 NeoStem Head-to-Head with Baxter in the HSC Cardiovascular Treatment Space
    • 4.3.7 Aastrom Biosciences: Ixmyelocel-T for Cardiovascular Disease
      • 4.3.7.1 A Complex Multicellular Mixture
      • 4.3.7.2 Company Now Focusing on DCM
    • 4.3.8 Athersys - MultiStem is a Potential Cardiovascular Treatment
      • 4.3.8.1 Addressing Ischaemic Stroke
    • 4.3.9 CytoMedix - Three Clinical Candidates in the Cardiovascular Segment
      • 4.3.9.1 ALD-401 - Repairing Stroke Damage?
      • 4.3.9.2 ALD-301 - Entering Phase 2 in PAD Patients
      • 4.3.9.3 ALD-201 - Signs of Efficacy in Phase 1 Heart Failure Trial
    • 4.3.10 TCA Cellular Therapy - Mesendo Autologous Treatments
      • 4.3.10.1 Preparing for Phase 3 with CLI Treatment
    • 4.3.11 Medistem - The 'Universal Donor' Cell
      • 4.3.11.1 Trial in CLI the First Clinical Test for ERC
      • 4.3.11.2 Scalability a Major Advantage for Medistem
    • 4.3.12 Stemedica Cell Technologies - Ischaemic Tolerant Stem Cell Platform
      • 4.3.12.1 Two Trials in Progress for Allogeneic MSCs
    • 4.3.13 Mesoblast - Cell Therapy for Myocardial Infarction
      • 4.3.13.1 Teva Collaborating on Cardiovascular Stem Cell Therapy R&D
    • 4.3.14 Pluristem - Cell Therapy for Myocardial Infarction
      • 4.3.14.1 Progress in PAD and CLI
    • 4.3.15 Osiris - Prochymal Cell Therapy for Myocardial Infarction
    • 4.3.16 Cytori Therapeutics - Adipose-Derived Cells for Acute Myocardial Infarction
    • 4.3.17 Stempeutics - Emerging Bangalore Company Targets CLI
    • 4.3.18 BioCardia - Comparing Autologous and Allogeneic MSCT Options
    • 4.3.19 Apceth - Mesenchymal Stem Cells for Advanced Peripheral Arterial Occlusive Disease
    • 4.3.20 Arteriocyte - Nanex Technology to Treat CLI
    • 4.3.21 Capricor - Using Cardiosphere-Derived Cells for Heart Repair
      • 4.3.21.1 Phase 1/2 Trial Now Underway
    • 4.3.22 Garnet BioTherapeutics - GBT009 for Cardiac Tissue Preservation
    • 4.3.23 Biogenea-Cellgenea - Cardiogenea to Enter the Clinical Pipeline
    • 4.3.24 Other Stem Cell Cardiovascular Prospects
  • 4.4 Can Stem Cells Be a Game-Changer in the Cardiovascular Sphere?

5. Stem Cell CNS Therapeutics Segment, 2013-2023

  • 5.1 The Biggest Stem Cell Therapeutic Revolution of All will Begin to Take Shape by 2023
  • 5.2 Stem Cells the Best Hope for Many Serious CNS Conditions
    • 5.2.1 Segment Awaits First Breakthrough Approval
    • 5.2.2 Human NSCs Successfully Isolated
    • 5.2.3 NSCs Reach the Clinic
    • 5.2.4 CNS Segment the Major Focus for ESC Research
    • 5.2.5 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
    • 5.2.6 Could 'Resetting' the Immune System Treat MS?
    • 5.2.7 ALS: Rare Disease Could be the First Neurodegenerative Condition to Fall to Stem Cell Treatment
    • 5.2.8 PD: Positive Signs from Early Experiments in Cellular Treatment
    • 5.2.9 Dry AMD: A Major Global Unmet Need
    • 5.2.10 Several Multi-Billion Dollar Potential Markets in the Sights of CNS Stem Cell Developers
  • 5.3 Which Product Will Be First to Phase 3 Trials in the CNS?
    • 5.3.1 BrainStorm Cell Therapeutics - NurOwn Cells for Spinal Cord Injury and ALS
      • 5.3.1.1 Validating the NurOwn Approach
      • 5.3.1.2 ALS Trial Ongoing
    • 5.3.2 Neuralstem - Neural Stem Cells for Synaptic Repair and Neuroprotection
      • 5.3.2.1 Phase 2 Trial in ALS Enrolling by Invitation
      • 5.3.2.2 Chronic Spinal Cord Injury Treatment to Follow
    • 5.3.3 Mesoblast - A New Option in Neovascular AMD?
      • 5.3.3.1 CNS Stem Cells from Dental Pulp
    • 5.3.4 Advanced Cell Technology - Leading the Field in ESC Clinical Trials
      • 5.3.4.1 Continued Progress in Stargardt's Macular Dystrophy in 2013
      • 5.3.4.2 Early Signals of Efficacy?
    • 5.3.5 StemCells - The Leading Player in the NSC Space?
      • 5.3.5.1 HuCNS-SC Product Proving Itself in Rare Indications
      • 5.3.5.2 Moving on to Spinal Cord Injury and AMD
      • 5.3.5.3 Alzheimer's Disease and Stroke to Follow?
    • 5.3.6 TCA Cellular Therapy - Mesendo for ALS
    • 5.3.7 Corestem - Autologous Bone Marrow Stem Cells for ALS
    • 5.3.8 ReNeuron - ReN001 is a Potential New Stroke Treatment
      • 5.3.8.1 Foetally-Sourced Cells Have Wide Potential Application
    • 5.3.9 SanBio - SB623 for Ischaemic Stroke
      • 5.3.9.1 Future SanBio Programmes at Preclinical Stage in 2013
    • 5.3.10 Pfizer - Collaborating on the London Project to Cure Blindness
    • 5.3.11 Stemedica Cell Technologies- Ischaemic RPE Cells
      • 5.3.11.1 NSC Lines from Donated Brain Tissue
    • 5.3.12 NeuroGeneration - Investigating Human NSCs
    • 5.3.13 Companies at Preclinical Stage
      • 5.3.13.1 RhinoCyte - Stem Cells from the Nasal Passage to the Spinal Cord
      • 5.3.13.2 Theradigm - Neural Cells for CNS Disorders
      • 5.3.13.3 Biotime - Targeting AMD with ESCs
    • 5.3.14 Other Companies with Technologies of Interest
      • 5.3.14.1 iPierian - Bringing iPSCs to the CNS Market?
  • 5.4 Will CNS Stem Cells Fulfil Their Perceived Therapeutic Potential?

6. Stem Cell Therapeutics in Other Disease Areas, 2013-2023

  • 6.1 A Diverse Range of Approvals will Drive Segment Growth to 2023
  • 6.2 Other Indications for Stem Cell Treatment
    • 6.2.1 Curing Orphan Diseases with HSCT
    • 6.2.2 Genetically-Modified HSCs May Cure HIV, Among Other Diseases
    • 6.2.3 Stem Cells for Osteogenesis
    • 6.2.4 Several Stem Cell Osteobiologics Already Marketed
    • 6.2.5 Perianal Fistula Treatment Indicates Stem Cells' Potential in Tissue Repair
    • 6.2.6 A New Option for Many Autoimmune Disorders
    • 6.2.7 Can Stem Cells Cure Diabetes?
    • 6.2.8 Mending the Liver
    • 6.2.9 Long-Range Possibilities
  • 6.3 Which Other Indications Will See the First Approvals?
    • 6.3.1 Medipost - Cartistem, 'World's First Allogeneic Stem Cell Drug'
    • 6.3.2 Anterogen - Cupistem, Adipose-Derived Stem Cells for Anal Fistula
    • 6.3.3 R&D Ranges Broadly Across Disease Areas
    • 6.3.4 TiGenix - Phase 3 Data for Cx601 Expected In July 2014
      • 6.3.4.1 'First Ever Signal of Clinical Activity of a Cell Therapy in RA'
      • 6.3.4.2 ChondroCelect Already on the Market
    • 6.3.5 Osiris Take on Crohn's Disease - Another Possible Use for Prochymal
      • 6.3.5.1 Chondrogen: New Osteoarthritis Candidate
    • 6.3.6 Mesoblast - Treating Back Pain and Disc Degeneration
      • 6.3.6.1 IV Precursor Cells Seeking Out New Indications
    • 6.3.7 Athersys - Pfizer Collaboration in Ulcerative Colitis
    • 6.3.8 Celgene Cellular Therapeutics - Targeting Multiple Inflammatory Conditions
    • 6.3.9 AlloCure - AC607 for Anti-Inflammatory Effects
    • 6.3.10 Gamida Cell - Potential Sickle Cell Anaemia Treatment Option
    • 6.3.11 GlaxoSmithKline - GSK2696273 Stem Cell Gene Therapy
    • 6.3.12 Alliancells Bioscience Corporation - Possible RA Treatment
    • 6.3.13 ViroMed - Stem Cell Gene Therapy for Chronic Granulomatous Disease
    • 6.3.14 S-Evans Biosciences - Menstrual Stem Cells for Hepatic Disease
    • 6.3.15 Cytomedix - ALD-601 for Lysosomal Storage Diseases
    • 6.3.16 Cellonis Biotechnology - Commercialising Research on Stem Cells in Diabetes
    • 6.3.17 Other Companies in the Hunt for New Stem Cell Applications
  • 6.4 Can We Expect A Clinical Breakthrough for Stem Cells in Other Therapeutic Areas by 2023?

7. Non-Therapeutic Applications of Stem Cell Technologies Segment, 2013-2023

  • 7.1 Cell-Based Assays will Help Expand this Segment in 2013-2023 Period
  • 7.2 A Diverse Range of Business Models Emerging
    • 7.2.1 Stem Cell Banking: Growing Demand Worldwide
    • 7.2.2 Stem Cell Supply and Processing: iPSCs the New Driver?
    • 7.2.3 Stem Cell-Based Assays: Major Potential for Preclinical Screens
    • 7.2.4 Research, Reagents, and Other Non-Therapeutic Stem Cell Revenue Streams
  • 7.3 What Will the Main Growth Areas be for Non-Therapeutic Stem Cell Activities?

8. Qualitative Industry Analysis, 2013

  • 8.1 Strengths: Stem Cells Are Finally Proving Their Worth
  • 8.2 Weaknesses: Many Difficulties Still to Overcome
  • 8.3 Opportunities: Stem Cells Have Unprecedented Clinical Potential
  • 8.4 Threats: Regulatory and Commercial Instability Threatens the Field
  • 8.5 Social Concerns: A Controversial Technology
  • 8.6 Technological Developments: Stem Cell Science Still on the March
  • 8.7 Economic Factors: Funding Gaps a Concern
  • 8.8 Political Issues: State Attitudes Key to Research Environment

9. Research Interviews

  • 9.1 Interview with Dr Antonio Lee, Associate Director Business Development, Medipost
    • 9.1.1 Overview of Cartistem
    • 9.1.2 Global Regulatory Variation in Cellular Cartilage Repair Field
    • 9.1.3 Precedents and Competition for Cartistem
    • 9.1.4 Cord Blood-Derived MSCs: Advantages and Challenges
    • 9.1.5 Medipost's Pipeline
  • 9.2 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)
    • 9.2.1 Improved Funding in the Stem Cells Field
    • 9.2.2 MSCs: Major Potential or Merely a Placeholder?
    • 9.2.3 CIRM Investment Strategies
    • 9.2.4 The Changing Regulatory Environment Worldwide
    • 9.2.5 Key Trends for the Next Five to Ten Years
  • 9.3 Interview with Dr Andras Nagy, Senior Scientist, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
    • 9.3.1 Overview of the Current State of the iPSC Field
    • 9.3.2 Genomic Stability and Other Potential Issues for iPSCs
    • 9.3.3 Potential for Treating and Modelling Diseases with iPSCs
    • 9.3.4 Reprogramming Without Transgenes
    • 9.3.5 Possibilities for Directly-Converted Cells

10. Conclusions

  • 10.1 Stem Cell Technologies Will Begin to Break Through by 2017
  • 10.2 Market to Record Double-Digit CAGR to 2023
  • 10.3 Oncology and Non-Therapeutic Uses to Dominate To 2017
  • 10.4 CNS and Cardiovascular Treatments to Gain Market Share by 2023
  • 10.5 Strong R&D Pipeline to Drive Market Growth
  • 10.6 Radical Clinical and Commercial Possibilities for Stem Cells in the Longer Term
  • 10.7 Challenges for the Stem Cells Market
  • 10.8 Concluding Remarks

List of Tables

  • Table 2.1 Stem Cells Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 2.2 Stem Cells Market: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 2.3 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
  • Table 2.4 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017
  • Table 2.5 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
  • Table 2.6 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023
  • Table 2.7 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
  • Table 2.8 Potency and Source of Stem Cells
  • Table 2.9 Germ Layers and Their Associated Types of Cells and Organs
  • Table 2.10 Main Types of Stem Cells and Their Properties, 2013
  • Table 2.11 Sources of Stem Cells for Medical Applications, 2013
  • Table 3.1 Cancer Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 3.2 Cancer Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 3.3 Comparative Characteristics of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2013
  • Table 3.4 Indications with Medicare Coverage for HSCT, 2013
  • Table 3.5 Malignancies and Other Haematological Diseases Treated with HSCT, 2013
  • Table 3.6 Selected Companies Developing Stem Cell Cancer Treatments, 2013
  • Table 4.1 Cardiovascular Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 4.2 Cardiovascular Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 4.3 Selected Companies Developing Stem Cell Cardiovascular Treatments, 2013
  • Table 5.1 CNS Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 5.2 CNS Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 5.3 Selected Companies Developing Stem Cell Cancer Treatments, 2013
  • Table 6.1 Other Therapeutic Areas Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 6.2 Other Therapeutic Areas Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 6.3 Diseases Other than Cancers to be Treated with HSCT, 2013
  • Table 6.4 Processes Involved in Bone Healing
  • Table 6.5 Selected Companies Developing Stem Cell Cancer Treatments, 2013
  • Table 7.1 Non-Therapeutic Applications Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 7.2 Non-Therapeutic Applications Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 7.3 Non-Therapeutic Applications of Stem Cells: Estimated Breakdown of Activities, Revenues ($m), Segment Share (%), 2012
  • Table 7.4 Selected US Stem Cell Banking Companies, 2013
  • Table 7.5 Selected Non-US Stem Cell Banking Companies, 2013
  • Table 7.6 Selected Stem Cell Supply and Processing Companies, 2013
  • Table 7.7 Selected Companies with Involvement in Stem Cell-Based Assays, 2013
  • Table 7.8 Selected Companies with Other Stem Cell-Related Activities, 2013
  • Table 8.1 World Stem Cells Market: Strengths and Weaknesses, 2013
  • Table 8.2 World Stem Cells Market: Opportunities and Threats, 2013
  • Table 8.3 World Stem Cells Market: STEP Analysis, 2013-2023
  • Table 10.1 Stem Cell Products: Approved and in Late-Stage Trials, 2013

List of Figures

  • Figure 2.1 Stem Cells Market: Revenues ($m), 2012-2023
  • Figure 2.2 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
  • Figure 2.3 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
  • Figure 2.4 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
  • Figure 2.5 Stem Cells Market Breakdown by Segment: Revenues ($m), 2012-2023
  • Figure 2.6 Stem Cells Market Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
  • Figure 2.7 The Early History of Stem Cell Discovery and Development
  • Figure 3.1 Cancer Segment: Revenues ($m), 2012-2023
  • Figure 3.2 Drivers and Restraints for Stem Cell Cancer Therapies, 2013
  • Figure 4.1 Cardiovascular Segment: Revenues ($m), 2012-2023
  • Figure 4.2 Drivers and Restraints for Stem Cell Cardiovascular Therapies, 2013
  • Figure 5.1 CNS Segment: Revenues ($m), 2012-2023
  • Figure 5.2 Drivers and Restraints for CNS Stem Cell Therapeutics, 2013
  • Figure 6.1 Other Therapeutic Areas Segment: Revenues ($m), 2012-2023
  • Figure 6.2 Drivers and Restraints for Stem Cell Therapeutics in Other Therapeutic Areas, 2013
  • Figure 7.1 Non-Therapeutic Applications Segment: Revenues ($m), 2012-2023
  • Figure 7.2 Non-Therapeutic Applications of Stem Cells: Estimated Breakdown of Activities, Revenues ($m), Segment Share (%), 2012
  • Figure 7.3 Drivers and Restraints for Non-Therapeutic Applications of Stem Cells, 2013
  • Figure 10.1 Stem Cell Technologies Market Revenues ($m), 2012-2017
  • Figure 10.2 Stem Cell Technologies Market Revenues ($m), 2018-2023
  • Figure 10.3 Stem Cell Market Segments: Revenues ($m), 2012-2017
  • Figure 10.4 Stem Cell Market Segments: Revenues ($m), 2018-2023

Companies Listed

  • 3DM
  • Aastrom Biosciences
  • Adistem
  • Advanced Cell Technology
  • Alder Biopharmaceuticals
  • AllCells
  • Alliancells Bioscience Corporation
  • AlloCure
  • Amgen
  • Amorcyte
  • Angel Biotechnology
  • Angiostem
  • Angiotech
  • Anterogen
  • Antria
  • apceth
  • Aristotle University of Thessaloniki
  • Arteriocyte
  • Athersys
  • Auriga Ventures
  • Axiogenesis
  • Baxter Healthcare
  • Beth Israel Deaconess Medical Center
  • BioCardia
  • BioE
  • Biogenea-Cellgenea
  • Bioheart
  • Bio-Matrix
  • BioMet Orthopedics
  • Biotime
  • Bluebird Bio
  • BrainStorm Cell Therapeutics
  • Bresagen
  • California Institute for Regenerative Medicine (CIRM)
  • California Stem Cells
  • Capricor
  • Cardio3 Bioscience
  • Cardiogenesis
  • Cedars-Sinai Heart Institute
  • Celgene Cellular Therapeutics
  • Cell Cure Neurosciences
  • CellCentric
  • Cellectis
  • Cellerant Therapeutics
  • Cellonis Biotechnology
  • CellSeed
  • Cellular Dynamics International
  • Cephalon
  • Cha General Hospital
  • China Cord Blood Corporation
  • ChondroCelect
  • Clal Biotechnology Industries
  • Cognate BioServices
  • Cord Blood America
  • Corestem
  • Cryo-Cell International
  • CryoCord
  • Cryo-Save
  • CXR Biosciences
  • CyThera
  • Cytomedix
  • Cytori Therapeutics
  • Denali Ventures
  • Dendreon
  • Duke University
  • Elbit Imaging
  • Eli Lilly
  • EpiStem
  • ES Cell International
  • European Medicines Agency (EMA)
  • FCB-Pharmicell
  • FCB-Twelve
  • Food and Drug Administration (US FDA)
  • Forticell Bioscience
  • Gamida Cell
  • Garnet BioTherapeutics
  • General BioTechnology
  • Geron
  • GlaxoSmithKline
  • Global Stem
  • GMP Unlimited
  • Greenpeace
  • Hadassah Medical Organization
  • Harvard Stem Cell Institute
  • Histostem
  • HomeoTherapy
  • Human Fertilisation and Embryology Authority (HFEA)
  • Human Stem Cell Institute
  • ImmunoCellular Therapeutics
  • Immunovative Therapies
  • InSCeption Biosciences
  • Institute of Biomedical Research (Japan)
  • IntelliCell Biosciences
  • International Stemcell Services
  • iPierian
  • iPS Academia Japan
  • Israel Healthcare Venture
  • Israel Stem Cell Society
  • Ixion Biotechnology
  • Johnson & Johnson
  • Lentigen
  • Lifebank Cryogenics
  • LifebankUSA
  • MaRS Innovation
  • Maxcyte
  • MedCell Bioscience
  • Medical Research Council (UK)
  • Medipost
  • Medistem Laboratories
  • Merck & Co.
  • Merck Millipore
  • Mesoblast
  • MetaCyte Business Lab
  • Miltenyi Biotec
  • Ministry of Food and Drug Safety, Korea
  • National Marrow Donor Program (US)
  • NeoStem
  • Neuralstem
  • NeuroGeneration
  • NeuroSearch
  • Northern Therapeutics
  • Novartis
  • NovoCell
  • NsGene
  • NuVasive
  • OncoCyte
  • Opexa Therapeutics
  • OrbusNeich
  • OrthoCyte
  • Orthofix
  • Osiris Therapeutics
  • Pfizer
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmicell
  • Plasticell
  • Pluristem Therapeutics
  • Progenitor Cell Therapy
  • Proneuron Biotechnologies
  • ReCyte Therapeutics
  • Regenerative Sciences
  • Regeneron
  • Regenetech
  • ReNeuron
  • Renovo Neural
  • RhinoCyte
  • Roslin Cellab
  • Rutgers University
  • Samuel Lunenfeld Research Institute, Mount Sinai Hospital
  • SanBio
  • Saneron CCEL Therapeutics
  • Sangamo BioSciences
  • Sanofi
  • Schepens Institute
  • Seoul National University
  • S-Evans Biosciences
  • Sirna Therapeutics
  • Skye Orthobiologics
  • South Korea Food and Drug Administration (KFDA)
  • Spinesmith Partners
  • Stem Cell Authority
  • Stem Cell Sciences
  • Stem Cell Therapeutics
  • Stemcell Technologies
  • StemCells
  • StemCore
  • StemCyte
  • Stemedica Cell Technologies
  • StemEx
  • StemGen
  • Stemina Biomarker Discovery
  • Stempeutics Research
  • Stemride International
  • Swissmedic
  • TCA Cellular Therapy
  • Teva Pharmaceutical Industries
  • Theradigm
  • Theratechnologies
  • TiGenix
  • United States District Court for the District of Columbia
  • United Therapeutics
  • University College London
  • University of California, San Diego
  • University of Heidelberg
  • University of Kyoto
  • University of Minnesota
  • University of Texas Health Science Center
  • University of Wisconsin Alumni Research Foundation
  • Vesta Therapeutics
  • ViaCell
  • ViaCyte
  • ViroMed Laboratories
  • Vitro Biopharma
  • World Health Organization (WHO)
  • Yonsei University
Back to Top